In the Spotlight...
Selective expansion of neoantigen-specific peripheral blood lymphocytes through antigen-presenting cell-T cell conjugate isolation
Autologous erythrocyte microparticles drive antitumour T cell immunity via haem-mediated dendritic cell activation
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Previous Digests
Not Cullin it quits: removing CRL5 sustains T cell function in tumors
October 28, 2026
The lack of persistence after adoptive T cell therapies due to T cells becoming dysfunctional under chronic exposure to tumor antigens limits their efficacy. Two recent back-to-back publications by Bachl et al. and Saco et al. in Cancer Immunology...
New PrimeCAR protocol delivers improved CAR T cells in less time
October 21, 2026
CAR T cells are a powerful treatment option for certain cancers, but their use can be limited by long manufacturing times and severe toxicities. In order to overcome these hurdles, Yang and Li et al. developed a new CAR...
Checkpoints for the win: neoadjuvant ICB outperforms targeted therapy in melanoma
October 14, 2026
Neoadjuvant treatment with immunotherapy and/or targeted agents has become standard of care for resectable stage IIIB-D melanoma. However, the optimal treatment regimen and the consequences for long-term survival remain largely unknown. Long et al. analyzed a large dataset of...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
